Myriad Genetics highlights 2022 research findings

Myriad Genetics highlighted impactful clinical studies from 2022 that underscore the company’s commitment to making genetic testing more accessible and equitable for all patient populations. To advance precision medicine, Myriad is dedicated to ongoing research and has published evidence demonstrating technological and scientific innovation in the areas of mental health, oncology, and women’s health. Highlights from 2022 include: Myriad and researchers from several collaborating institutions described the development and validation of RiskScore, a breast cancer polygenic risk score for women of all ancestries, in a study published in JCO Precision Oncology. Consistent with Myriad’s goal of supporting equitable cancer risk assessment, RiskScore is the first risk prediction model that combines a PRS validated for women of all ancestries with clinical and biological variables. The combinatorial approach used by the GeneSight Psychotropic test exceeds the effectiveness of single-gene testing at predicting sertraline metabolism in patients with major depressive disorder, as demonstrated in a study published in Psychiatry Research. The GeneSight algorithm assists providers in choosing medications that will be most effective for each of their patients, improving access to personalized care for those with depression. Myriad researchers identified a carrier screening panel that is consistent with professional society guidelines and supports equity in care compared to ethnicity-specific carrier screening programs. The study, published in Genetics in Medicine, determined that the panel would identify more than 96% of couples at risk of having children with a serious disease, regardless of their ethnicity. Prolaris predicts which patients can safely forego Androgen Deprivation Therapy and still have a low risk of metastasis, as shown in a study published in The International Journal of Radiation Oncology, Biology and Physics. This helps patients and their providers make personalized decisions about what type of therapeutic regimen will be most effective while avoiding unwanted side effects. Results from EndoPredict are significantly associated with risk of distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer, shown by a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. EndoPredict provides information to premenopausal women regarding whether they have a very low recurrence risk and could therefore safely avoid adjuvant chemotherapy as part of their treatment plans. A version of the MyChoice Homologous Recombination Deficiency assay can be successfully run in a decentralized fashion, according to a study published in the Journal of Molecular Diagnostics by Myriad researchers and collaborators. MyChoice provides important information about treatment strategies for patients with ovarian cancer, and the ability of other laboratories to offer the HRD assay increases patient access to this test.